Longeveron's Lomecel-B Shows Promise in HLHS and Alzheimer's Disease Trials
Key Insights
Longeveron's ELPIS II trial for HLHS, evaluating Lomecel-B™, has surpassed 80% enrollment and is deemed pivotal by the FDA for BLA submission.
Positive Phase 2a data from the CLEAR MIND trial, assessing Lomecel-B™ in mild Alzheimer's, was highlighted at the Alzheimer's Association International Conference.
Longeveron reported a 177% increase in revenue for the first nine months of 2024, driven by contract manufacturing and Bahamas Registry Trial demand.
Longeveron Inc. (NASDAQ: LGVN) is making strides in its clinical programs for Lomecel-B™, a cellular therapy, targeting Hypoplastic Left Heart Syndrome (search) (HLHS) and Alzheimer's disease. The Phase 2b ELPIS II trial for HLHS has achieved over 80% enrollment and received confirmation from the FDA that it is a pivotal trial. Positive data from the Phase 2a CLEAR MIND trial in mild Alzheimer's disease were presented at the Alzheimer's Association International Conference (AAIC).
HLHS Program Advances
The ELPIS II trial, a Phase 2b study evaluating Lomecel-B™ as an adjunct therapy for HLHS, is enrolling 38 pediatric patients across twelve institutions. The FDA has confirmed that positive results from ELPIS II could support a Biological License Application (BLA) submission for full traditional approval. This trial builds upon the ELPIS I study, where children treated with Lomecel-B™ experienced 100% transplant-free survival up to five years of age, compared to an approximate 20% mortality rate in historical controls. The FDA has granted Lomecel-B™ Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS.
Alzheimer's Disease Data Show Promise
Longeveron presented full results from the Phase 2a CLEAR MIND trial at the AAIC, supporting the therapeutic potential of Lomecel-B™ in mild Alzheimer's disease. The data provide evidence for further clinical development. The FDA has granted Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for mild Alzheimer's disease. Further data presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) indicated that Lomecel-B™'s capacity to inhibit MMP14 (search) correlates with improved clinical and biomarker outcomes in mild Alzheimer’s disease (search).
Financial Update
Longeveron reported a 177% year-over-year increase in revenue for the first nine months of 2024, reaching $1.8 million. This growth was primarily driven by increased demand for the Bahamas Registry Trial and contract manufacturing services. The company's cash and cash equivalents are expected to fund operations through the fourth quarter of 2025. However, the company anticipates meeting with the FDA in the first quarter of 2025 to review future clinical and regulatory strategy.